Edition:
India

Celyad SA (CYAD.OQ)

CYAD.OQ on NASDAQ Stock Exchange Global Market

41.25USD
2:29am IST
Change (% chg)

$1.22 (+3.05%)
Prev Close
$40.03
Open
$40.05
Day's High
$41.25
Day's Low
$39.86
Volume
482
Avg. Vol
1,335
52-wk High
$64.00
52-wk Low
$17.24

Latest Key Developments (Source: Significant Developments)

Celyad ends Q3 with EUR 40 million in cash, confirms previous guidance
Friday, 17 Nov 2017 

Nov 17 (Reuters) - CELYAD SA ::ENDED THE QUARTER WITH EUR 40 MILLION IN CASH.CONFIRMS ITS PREVIOUS GUIDANCE THROUGH TO THE FIRST HALF 2019.  Full Article

Celyad H1 loss widens to 16.9 million euros
Thursday, 25 Aug 2016 

Celyad SA : H1 loss of EUR 16.9 million ($19.05 million) versus loss of EUR 15.3 million year ago . Says ended the first half of 2016 with EUR 86 million in cash and short-term deposits .Says amount in treasury should enable to fund operating expenses and capital expenditure requirements until the end of 2018.  Full Article

Celyad says early signing agreement with ONO is because of interest of companies - conf call
Monday, 11 Jul 2016 

Celyad SA : Reason for early signing agreement with ONO Pharmaceutical <4528.T> is because of interest of companies to do so - conf call . In order for deal in US or Europe, would have to be "extremely compelling" for us at this stage - conf call . Within next 12 months we should expect second milestone - conf call . Royalty rate is same for all 3 countries - conf call . On C-Cure: discussions with EMA in Q3 - conf call . Japanese partnership has been relatively expedited - conf call Further company coverage: [CYAD.BR] (Gdynia Newsroom) ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;)).  Full Article

Celyad enters into license agreement with ONO Pharmaceutical
Monday, 11 Jul 2016 

Celyad SA : Celyad enters into license agreement with ONO pharmaceutical Co., Ltd. <4528.T> to develop allogeneic NKR-2 T-cell immunotherapy . Celyad grants an exclusive license to ONO for development and commercialization of Celyad's allogeneic NKR-2 t-cell in Japan, Korea and Taiwan . Celyad also grants to ONO an exclusive option to license its autologous NKR-2 t cell product in above ONO territories. . Total deal value of up to JPY 31.325 bln (282 mln euros or $311.5 mln) plus double digit royalties on net sales in ono territories . Celyad will receive an upfront payment of JPY 1.25 bln (11.25 million euros or $12.5 million) . Celyad is eligible of up to JPY 30.075 bln (270.75 mln euros or $299 mln) in development and commercial milestones .Will also receive double digit royalties based on net sales of licensed product in ONO's territories.  Full Article

Celyad says study has not succeeded - conference call
Tuesday, 28 Jun 2016 

Celyad SA : Says study has not succeeded - conf call . Says with p-value witnessed optimistic that a partner will take this further in the U.S. - conf call . Says some of the elements reached a statistical significance while others have not - conf call . Says there are companies that have expressed interested to partner with us after the data has been released - conf call . Says there is no certainty to get EMA authorization - conf call . Says they will not progress in a second trial without a partner - conf call . Says will look for partners in Europe as well - conf call . Says not sure when partnership will materialize; can be before during or after discussions with EMA - conf call . Says plans to partner to commercialize the product if EMA approval - conf call . Says if no partner by the time of EMA approval will look into potentially spinning off product to commercialize product in seperate entity - conf call . Says expects EMA guidance in the next 3-4 months - conf call Further company coverage: [CYAD.BR] (Gdynia Newsroom:) ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;)).  Full Article

Celyad CHART-1 Phase III trial shows no significant difference on primary endpoint
Tuesday, 28 Jun 2016 

Celyad SA : Announces results CHART-1 Phase III clinical trial evaluating c-cure cell therapy . Statistically-significant difference on the primary endpoint was not reached . Based on the positive subgroup analysis, Celyad will contact the European Medicines Agency concerning a marketing authorization application . Primary endpoint was met (p=0.015) for a subset representing 60 pct of the population of the CHART-1 study . Celyad will seek a partner to accelerate further development and commercialization of C-Cure . Trading in celyad stock will be suspended on June 28, 2016, until the completion of the conference call scheduled at 2:00 pm CEST .The study procedure was well tolerated with no safety concerns.  Full Article

Celyad: cash of 94.7 million euro at end of Q1
Thursday, 19 May 2016 

Celyad SA :Cash of 94.7 million euro ($106.2 million) at end of Q1 2016.  Full Article

Celyad SA updates on NKR-2 trial
Wednesday, 30 Mar 2016 

Celyad SA:Successfully completes safety follow-up of the first patient in the third dose level of its NKR-2 trial.No safety issues were reported.  Full Article

Celyad announces collaboration with Institut Curie for development of its immuno-oncology program NKR-T
Tuesday, 22 Mar 2016 

Celyad SA:Celyad announces collaboration with Institut Curie for development of its immuno-oncology program NKR-T.  Full Article

Celyad notifies intention to file marketing authorization application for C-Cure
Friday, 18 Mar 2016 

Celyad SA:Notifies the European Medicines Agency (EMA) of its intention to file a marketing authorization application (MAA) for C-Cure.Is optimistically awaiting chart-1 phase III results which are expected end of june 2016.  Full Article

BRIEF-Celyad ends Q3 with EUR 40 million in cash, confirms previous guidance

* CONFIRMS ITS PREVIOUS GUIDANCE THROUGH TO THE FIRST HALF 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)